Cargando…
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders?
OBJECTIVES: RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response. METHODS: We enrolled RA...
Autores principales: | Ibrahim, Fowzia, Lorente-Cánovas, Beatriz, Doré, Caroline J, Bosworth, Ailsa, Ma, Margaret H, Galloway, James B, Cope, Andrew P, Pande, Ira, Walker, David, Scott, David L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722050/ https://www.ncbi.nlm.nih.gov/pubmed/28968858 http://dx.doi.org/10.1093/rheumatology/kex315 |
Ejemplares similares
-
Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018) -
Adalimumab concentration-based tapering strategy: as good as the recommended dosage
por: Mulleman, Denis, et al.
Publicado: (2018) -
T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study
por: Lang Kuhs, Krystle A., et al.
Publicado: (2018) -
Good Laboratory Practices: Tyl Responds
por: Tyl, Rochelle W.
Publicado: (2010) -
Antiangiogenesis in recurrent glioblastoma: proof of principle
por: Nossek, Erez, et al.
Publicado: (2009)